Document is current
Any future updates will be listed below
-
Authors
Richardson, Tyrique
Hou, Xu
Fiesel, Fabienne C.
Wszolek, Zbigniew K.
Dickson, Dennis W.
Springer, Wolfdieter
-
Funding
Funding for this research was provided by:
Alzheimer's Association (AARF-22-973152)
National Institute of Neurological Disorders and Stroke (R56 AG062556)
- License Information
-
More Information
Article History
Received: 22 November 2024
Accepted: 12 February 2025
First Online: 24 February 2025
Declarations
:
: All brain samples are from autopsies performed after approval by the legal next-of-kin. Research on de-identified postmortem brain tissue is considered exempt from human subjects’ regulations by the Mayo Clinic Institutional Review Board.
: Not applicable.
: Mayo Clinic, F.C.F., and W.S. hold a patent related to PRKN activators (Small Molecule Activators of Parkin Enzyme Function, US patent, 11401255B2; August 02, 2022). Z.K.W. serves as PI or Co-PI on projects/grants from Biohaven Pharmaceuticals, Inc., Vigil Neuroscience, Inc., ONO Pharmaceuticals Co., LTD., and Amylyx Pharmaceuticals, Inc., and he is an external advisory board member for Vigil Neuroscience, Inc., and a consultant on neurodegenerative medical research for Eli Lilly & Company and NovoGlia Inc. All other authors declare they have no competing interests. This research was conducted in compliance with Mayo Clinic conflict of interest policies.
